Determinants of platelet catecholamine content: uptake and retention of catecholamines by human platelets in vitro

A J Zweifler1, I Fedorak, M Borondy

  • 1Division of Hypertension, Department of Internal Medicine, The University of Michigan Hospitals, 1500 E. Medical Center Drive, Ann Arbor, Michigan, 48109-0356, USA.

Platelets
|November 4, 2010
PubMed

The utility of platelet catecholamine determination in assessing sympathetic nervous system activity depends on the extent to which transient fluctuations of plasma catecholamine concentration can affect platelet catecholamine content. In order to quantitate the relationship between plasma and platelet catecholamine content, the concentrations of norepinephrine, epinephrine and dopamine needed to produce an increase in platelet catecholamines in vitro were determined. The threshold for epinephrine accumulation was 10(-9)M while the thresholds for norepinephrine and dopamine were an order of magnitude higher. The uptake of catecholamines was also found to differ with regard to the time course and the amount of catecholamine accumulated. For example, after 2 h in the presence of equimolar (2 × 10(-8)M) concentrations of catecholamine the platelet content of norepinephrine doubled and epinephrine rose 10-fold and dopamine 20-fold. When platelets that had been loaded with catecholamines were suspended in catecholamine-free buffer, significant amounts of catecholamines were still retained in the platelets after 3 h, but retention of norepinephrine was greater than that of epinephrine. These results indicate the importance of the concentration of the particular catecholamine, duration of exposure of platelets to the catecholamine and the ability of platelets to retain catecholamines, in determining the relationship between plasma and platelet catecholamine content.

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...